Navigation Links
Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes
Date:10/28/2009

SAN DIEGO, Oct. 28 /PRNewswire/ -- Novocell, Inc., a preclinical stage diabetes company, today announced that it will receive a Disease Team award totaling $20 million from the California Institute for Regenerative Medicine (CIRM). The Disease Team includes a group of scientists at the University of California, San Francisco (UCSF), led by Dr. Jeff Bluestone, which is contracted to receive $2.8 million. The funding will advance Novocell's development of a first in kind cellular therapy for the treatment of diabetes.

Novocell's proposal was selected for funding by CIRM's governing board, the Independent Citizens Oversight Committee (ICOC), with advisement from the Scientific and Medical Research Funding Working Group. "Novocell's proposal addresses an unmet medical need, contains compelling preliminary data in animals and is backed by a high quality team of scientists. It is the expectation that all Disease Team award recipients will be entering the clinic after the funding period. Novocell's systematic approach is expected to do just that, and as a consequence, CIRM and the ICOC decided to fund Novocell's efforts," said Allan Trounson, President of CIRM.

Nearly 25 million people in the United States are afflicted with diabetes. Many diabetics have loss of insulin secreting cells resulting in poor blood sugar regulation. Novocell is developing an alternative to insulin injections by producing cells that will secrete insulin in patients similar to the cells that were lost. "We thank California voters for approving Proposition 71, and CIRM and the ICOC for their support of our science and scientists. This award will substantially accelerate our progress, which will benefit millions of Americans," said John West, President & Chief Executive Officer of Novocell.

"We are grateful for the confidence in our scientific team and the continuing financial support of our development efforts. The successful development of a stem cell therapy to alleviate the suffering of millions of Americans afflicted with diabetes is our passion. With the funding assistance from the state of California we can deliver the first cellular treatment for diabetes," said Emmanuel Baetge, Ph.D., Principal Investigator & Chief Scientific Officer of Novocell.

About CIRM

CIRM was established in November, 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. For more information, please visit www.cirm.ca.gov.

About Novocell

Novocell is a preclinical therapeutic company focused on diabetes. Our therapy is based on the encapsulation and implantation of pancreatic beta cell progenitors (Pro-Islet-1) derived from human stem cells which secrete insulin in patients. Our goal is that Pro-Islet-1 can free both Type 1 and Type 2 diabetic patients from insulin dependence on a long term basis, while reducing or eliminating hypoglycemic, microvasculature and weight-mediated cardiovascular complications. Novocell is a private company headquartered in San Diego, California, with additional operations in Athens, Georgia.

SOURCE Novocell, Inc.


'/>"/>
SOURCE Novocell, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice
2. Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors
3. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
4. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
5. Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance To Enter U.S. Transfusion Diagnostics Market
6. Athera Receives Allowance of Two Key Patents
7. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
8. AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy
9. CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
10. Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit
11. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  MIODx announced today that ... key immunotherapy technologies from the University of California, ... method to monitor a patient for response to ... CTLA-4.  The second license extends the technology with ... likely to have an immune-related adverse event (IRAE) ...
(Date:2/23/2017)... 23, 2017  Seattle,s upscale Capitol Hill neighborhood, with its swanky ... for a head lice treatment salon to set up shop. ... restaurant and a French bistro on E Madison Ave, and ... just any old lice clinic, we pride ourselves on being ... release some of the stigma associated with lice. Everyone can ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, ... begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. ... healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed on ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... annual Inventors Recognition Reception at Purdue Research Park of West Lafayette, ... in recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 About Voice Recognition Biometrics Voice recognition ... against a stored voiceprint template. Acoustic features of ... tone are compared to distinguish between individual voices. ... most PCs already have a microphone and can ... biometrics are most likely to be deployed in ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
Breaking Biology News(10 mins):